OHE Publications

OHE releases a number of publications throughout the year, authored by OHE team members and/or outside experts. All are free for download as pdf files; hard copies of some publications are available upon request.

A description of the OHE publications categories.


 

Cookson, R. and Claxton, K. eds.

Monograph
November 2012

The Humble Economist is an outstanding collection of the most important essays by Prof Tony Culyer, a founding father of health economics. It distils a powerful set of ideas that have profoundly influenced health policy and decision making, and shows how reason and evidence can be used to improve decision making in any area of social policy.

Persson, U.

Seminar Briefing
November 2012

In this Seminar Briefing, Ulf Persson recounts Sweden’s experience with its approach to value based pricing (VBP). The model is a flexible approach that gives weight to cost-offsets outside the health sector and emphasises both encouraging innovation and enhancing access through such options as coverage with evidence development. He offers a series of examples to demonstrate how Sweden has addressed issues that any VBP system will face, including access to orphan drugs.

O’Neill, P., Puig-Peiro, R., Mestre-Ferrandiz, J. and Sussex, J.

Consulting Report
October 2012

Since 1996, in its yearly PPRS Report to Parliament, the Department of Health in England has published international price comparisons of branded medicines used in the primary care setting. OHE Consulting uses the same methodology in this report to update comparisons through 2011.

Riccaboni, M.

Seminar Briefing
June 2012

This Seminar Briefing recounts the key points made by Prof Riccaboni, from the University of Trento, at a recent OHE Lunchtime Seminar.  It focuses primarily on the reasons for a decline since 2000 in the average number of new drugs launched per year by the pharmaceutical industry.  Factors identified as important include a trend towards targeting more complex and difficult diseases, the need to adapt to dramatic changes in scientific knowledge and in R&D approaches, and substantial changes in both the regulatory and marketing climates.

Mestre-Ferrandiz, J., Mordoh, A. and Sussex, J.

Consulting Report
June 2012

This report provides a clear explanation of the nature of innovation in medicines.  A fully revised and expanded version of the 2005 edition, it updates the literature review of the economics of innovation, traces important innovation that has occurred since 2005, adds new case studies and updates the discussion of competition in pharmaceutical R&D.

Garau, M., Towse, A., Garrison, L., Housman, L. and Ossa, D.

Research Paper
April 2012

Diagnostics not only facilitate health gain and cost savings, but also provide information to inform patients’ decisions on interventions and to clarify how their behaviour may affect their health. Current pricing and reimbursement systems for diagnostics, however, are not efficient and provide poor incentives for new diagnostic approaches.  Prices often are driven by administrative practice and expected production cost, rather than assessments of value.

Feng, Y., May, A., Farrar, S. and Sutton, M.

Research Paper
April 2012

In April 2006, payment thresholds were raised for GPs who participate in Scotland’s Ouality and Outcomes Framework.  GPs were required to meet new, higher thresholds on some indicators to receive maximum levels of payment.  In this paper, OHE’s Yan Feng and her colleagues examine whether this change in fact improved GP performance and whether the impact differed across GPs. Specifically, they examine whether low-, mid- and high-performing GPs changed behaviour and, if so, to what extent.

Feng, Y., Parkin, D. and Devlin, N.

Research Paper
April 2012

The NHS Patient Reported Outcome Measures (PROMs) programme, introduced in April 2009, is a significant development in the routine collection and use of patient reported outcome data.  Data currently are collected for patients both before and after surgery for four elective surgical procedures in the NHS, with plans to expand the practice.

Towse, A., Garrison, L. and Puig-Peiro, R.

Occasional Paper
February 2012

Interest is growing in schemes that involve “paying for pills by results”, that is, “paying for performance” rather than merely “paying for pills”.  Despite its intuitive appeal, this approach is highly controversial and is disliked by many health care providers, policy makers, and pharmaceutical companies.

Pages